4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings (Duclorexint)
Primary Purpose
Hospital Infection
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
4% chlorhexidine gluconate soap-like solution
standard soap
Sponsored by
About this trial
This is an interventional prevention trial for Hospital Infection focused on measuring 4% chlorhexidine gluconate, infection control
Eligibility Criteria
Inclusion Criteria:
- admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU (PC-ICU)
- ICU/PC-ICU stay for at least 1 night
Exclusion Criteria:
- known allergy to chlorhexidine
- burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis
- pregnancy
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Intervention Arm
Control Arm
Arm Description
daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
daily bathing with standard soap
Outcomes
Primary Outcome Measures
hospital acquired infections incidence
cumulative incidence of bloodstream infections (BSI), central line-associates BSI (CLABSI), urinary tract infections (UTI), catheter-associated UTI (CAUTI) and ventilator-associated pneumonias (VAP)
Secondary Outcome Measures
Ventilator-associated pnemonias (VAP) incidence
VAP incidence
Bloodstream infections (BSI) incidence
BSI incidence
central-line associated BSI (CLABSI) incidence
CLABSI incidence
urinary tract infections (UTI) incidence
UTI incidence
catheter associated UTI (CAUTI) incidence
CAUTI incidence
4% CHG daily bathing safety
overall mortality in the treatment and control arm
4% CHG daily bathing-related adverse events
4% CHG daily bathing-related adverse events in the treatment arm compared to standard soap-related adverse events
time till infection
time between admission to ICU/PC-ICU and infection occurrence
Full Information
NCT ID
NCT03639363
First Posted
August 13, 2018
Last Updated
August 17, 2018
Sponsor
University Of Perugia
Collaborators
Fondazione Toscana Gabriele Monasterio
1. Study Identification
Unique Protocol Identification Number
NCT03639363
Brief Title
4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings
Acronym
Duclorexint
Official Title
Study on the Effect of the Universal Decontamination With Daily Bathing With 4% Chlorhexidine Gluconate on the Incidence of Hospital Acquired Infections in Intensive Care Units
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
August 10, 2015 (Actual)
Primary Completion Date
April 28, 2016 (Actual)
Study Completion Date
May 2, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Of Perugia
Collaborators
Fondazione Toscana Gabriele Monasterio
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The study will assess the utility of 4% chlorhexidine gluconate (CHG) daily bathing to reduce hospital acquired infections in patients admitted to intensive care units. One group will be daily bathed with 4% CHG and the other group with standard soap.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hospital Infection
Keywords
4% chlorhexidine gluconate, infection control
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
449 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Intervention Arm
Arm Type
Experimental
Arm Description
daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
daily bathing with standard soap
Intervention Type
Drug
Intervention Name(s)
4% chlorhexidine gluconate soap-like solution
Intervention Description
humidify the whole body surface with the exception of the face using water-impregnated washcloths
use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG
wait for at least 30 seconds
rinse using water-impregnated washcloths
Intervention Type
Other
Intervention Name(s)
standard soap
Intervention Description
humidify the whole body surface with the exception of the face using water-impregnated washcloths
use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face
wait for at least 30 seconds
rinse using water-impregnated washcloths
Primary Outcome Measure Information:
Title
hospital acquired infections incidence
Description
cumulative incidence of bloodstream infections (BSI), central line-associates BSI (CLABSI), urinary tract infections (UTI), catheter-associated UTI (CAUTI) and ventilator-associated pneumonias (VAP)
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Secondary Outcome Measure Information:
Title
Ventilator-associated pnemonias (VAP) incidence
Description
VAP incidence
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Title
Bloodstream infections (BSI) incidence
Description
BSI incidence
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Title
central-line associated BSI (CLABSI) incidence
Description
CLABSI incidence
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Title
urinary tract infections (UTI) incidence
Description
UTI incidence
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Title
catheter associated UTI (CAUTI) incidence
Description
CAUTI incidence
Time Frame
infections occured 48 hours after admission to ICU/PC-ICU
Title
4% CHG daily bathing safety
Description
overall mortality in the treatment and control arm
Time Frame
at discharge, approximately up to 10 days
Title
4% CHG daily bathing-related adverse events
Description
4% CHG daily bathing-related adverse events in the treatment arm compared to standard soap-related adverse events
Time Frame
at discharge, approximately up to 10 days
Title
time till infection
Description
time between admission to ICU/PC-ICU and infection occurrence
Time Frame
at discharge, approximately up to 10 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
admission to the intensive care unit (ICU) or to the post-operative cardiosurgical ICU (PC-ICU)
ICU/PC-ICU stay for at least 1 night
Exclusion Criteria:
known allergy to chlorhexidine
burns, toxic epidermal necrolysis or Stevens-Johnson syndrome as admission diagnosis
pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
franco baldelli, Professor
Organizational Affiliation
Infectious Diseases Clinical, University Hospital of Perugia, Perugia, Italy
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
30267930
Citation
Pallotto C, Fiorio M, De Angelis V, Ripoli A, Franciosini E, Quondam Girolamo L, Volpi F, Iorio P, Francisci D, Tascini C, Baldelli F. Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial. Clin Microbiol Infect. 2019 Jun;25(6):705-710. doi: 10.1016/j.cmi.2018.09.012. Epub 2018 Sep 26.
Results Reference
derived
Learn more about this trial
4% Chlorhexidine Gluconate Daily Bathing for Prevention of Hospital-acquired Infections in Intensive Care Settings
We'll reach out to this number within 24 hrs